Alport Syndrome

1. Clinical Overview

Summary

Alport syndrome is an inherited disorder of type IV collagen affecting the basement membranes of the kidney, cochlea, and eye, representing one of the most common genetic causes of end-stage renal disease (ESRD) in children and young adults. [1,2] The condition results from mutations in COL4A3, COL4A4 (chromosome 2q36-37), or COL4A5 (Xq22.3) genes, which encode the α3, α4, and α5 chains of type IV collagen respectively. [3] These chains are essential structural components of basement membranes in the glomerulus, cochlea, and eye.

The classic clinical triad comprises progressive renal disease (haematuria progressing to proteinuria and renal failure), bilateral sensorineural hearing loss, and characteristic ocular abnormalities (anterior lenticonus being pathognomonic). [1,4] However, the complete triad is present in only 30-40% of cases, making diagnosis challenging. X-linked inheritance accounts for approximately 80-85% of cases, with affected males invariably progressing to ESRD by age 20-40 years depending on mutation type. [5] Female carriers exhibit variable phenotypes ranging from isolated microscopic haematuria to progressive CKD. Autosomal recessive (10-15%) and autosomal dominant (5%) forms exist, with recessive cases phenotypically similar to severe X-linked disease. [6]

Management centres on early renin-angiotensin system (RAS) blockade with ACE inhibitors or ARBs, which can delay ESRD onset by approximately 10 years when initiated before significant proteinuria develops. [7,8] Renal transplantation is the preferred renal replacement therapy, with excellent outcomes comparable to other causes of ESRD, though 3-5% of patients develop post-transplant anti-GBM nephritis due to formation of alloantibodies against the "foreign" α3α4α5 collagen IV network. [9,10]

Key Facts

Clinical Pearls

The Hearing Clue: Sensorineural hearing loss in a young male with persistent haematuria is Alport syndrome until proven otherwise. The hearing loss typically begins at 6-8 kHz (high frequencies), is progressive, and precedes or coincides with declining renal function. By age 20-30, most affected males require hearing aids. [11]

X-Linked Pattern Recognition: The inheritance pattern is distinctive - affected males have severe disease, while carrier females show variable penetrance. Critically, affected males cannot transmit the X-linked form to their sons (no male-to-male transmission), but all daughters will be carriers. Mothers of affected males may have minimal or no symptoms but will have microscopic haematuria on careful testing.

Post-Transplant Anti-GBM Disease: Patients with large deletions or truncating mutations (who have never expressed normal α3α4α5 collagen IV) may develop de novo anti-GBM antibodies to the "new" collagen in transplanted kidneys, causing rapidly progressive crescentic glomerulonephritis. This typically occurs within the first post-transplant year and requires aggressive treatment with plasmapheresis and immunosuppression. [9,10]

The Lenticonus "Oil Droplet" Sign: Anterior lenticonus (forward bulging of the lens) is pathognomonic for Alport syndrome when present. On slit-lamp examination, it creates the characteristic "oil droplet" sign - a spherical reflection visible on the anterior lens capsule. This finding may not appear until the second or third decade. [4]

Thin GBM vs Alport: Early in disease, Alport syndrome may be indistinguishable from benign familial haematuria (thin basement membrane nephropathy). The key differentiator is progression - Alport shows progressive proteinuria, declining GFR, and extrarenal manifestations, whereas thin GBM disease remains benign. Genetic testing definitively distinguishes them. [12]

Why This Matters Clinically

Alport syndrome represents 2-3% of all ESRD cases and approximately 10% of children requiring renal replacement therapy, making it a significant cause of morbidity in young adults. [2] Early diagnosis is critical because:

1. Treatment efficacy is time-dependent: ACE inhibitors initiated before significant proteinuria develops (ACR less than 30 mg/mmol) can delay ESRD by a decade, but are far less effective once advanced proteinuria or renal impairment exists. [7,8]

2. Genetic counselling implications: As an inherited condition, diagnosis in a proband enables cascade family screening, allowing early identification and treatment of affected relatives, and informed reproductive choices.

3. Multisystem surveillance: Recognition prevents delays in audiology and ophthalmology referrals, enabling timely intervention for hearing loss (hearing aids, cochlear implants) and vision-threatening lenticonus.

4. Transplant planning: Knowledge of mutation type allows risk stratification for post-transplant anti-GBM disease, enabling closer monitoring and early intervention if alloantibodies develop. [9,10]

5. Prognostic precision: Genotype-phenotype correlations allow accurate counselling about likely disease trajectory - truncating mutations cause ESRD by age 20-25, while missense mutations may not cause ESRD until 30-40 years. [5]

---

2. Epidemiology

Incidence & Prevalence

Demographics

Inheritance Patterns & Genotype-Phenotype Correlations

X-Linked Genotype-Phenotype Correlations: [5]

Female Carriers (X-linked): [15]

• 95% have persistent microscopic haematuria
• 30% develop proteinuria by age 40
• 15-30% progress to ESRD (usually >age 60)
• 10% develop hearing loss
• Favourable X-chromosome inactivation patterns protect some carriers

Risk Factors for Progression

In X-linked females (risk factors for developing ESRD): [15]

• Proteinuria before age 30
• Hypertension
• Gross haematuria episodes
• Unfavourable X-inactivation pattern
• Specific mutation types (truncating mutations)

In all patients:

• Delayed diagnosis and treatment
• Untreated hypertension
• Concurrent nephrotoxic exposures
• Recurrent urinary tract infections

---

3. Aetiology & Pathophysiology

Molecular Genetics

Type IV Collagen Structure:

Type IV collagen is a major structural component of basement membranes throughout the body. It forms a complex network through:

1. Triple helix formation: Three α-chains (selected from α1-α6) form a collagenous heterotrimer
2. Network assembly: Trimers associate head-to-head and tail-to-tail to form meshwork
3. Tissue-specific expression: Different α-chain combinations in different tissues

Normal Collagen IV Networks: [3]

Genes and Mutations: [3,6]

Note: COL4A3 and COL4A4 are arranged head-to-head on chromosome 2, sharing a bidirectional promoter.

Pathophysiological Mechanism

Step 1: Genetic Mutation → Defective Collagen IV Chain

In Alport syndrome, mutations prevent proper synthesis, folding, or incorporation of α3, α4, or α5 chains:

• X-linked (COL4A5 mutation): α5 chain defective → α3α4α5 network cannot form → compensatory persistence of fetal α1α1α2 network [3]
• Autosomal (COL4A3 or COL4A4 mutation): α3 or α4 chain defective → same result (requires absence of both functional alleles in AR form)

Step 2: Abnormal Basement Membrane Composition

The α1α1α2 network that persists/predominates in Alport syndrome has different properties:

Step 3: Progressive Structural Damage to GBM

The structurally inferior α1α1α2 network undergoes characteristic ultrastructural changes: [16]

The Basket-Weave Pattern (pathognomonic on EM): [16]

• GBM shows irregular thickening and thinning
• Splitting of lamina densa into multiple layers
• Electron-dense granules within split areas
• Resembles woven basket on cross-section
• Best seen in 15-30 year old males

Step 4: Podocyte Injury & Proteinuria

As GBM integrity fails:

• Podocyte foot processes efface (loss of slit diaphragms)
• Filtration barrier incompetence → proteinuria
• Podocyte loss (irreversible) → progressive nephron loss
• Tubulointerstitial fibrosis and inflammation

Step 5: Progressive Renal Failure

Mechanisms of progression:

• Mechanical: Repeated haemodynamic stress on defective GBM → progressive damage
• Inflammatory: Red cell extravasation → tubular iron deposition → oxidative stress → fibrosis
• Proteinuric injury: Heavy proteinuria → tubular toxicity → interstitial inflammation
• Hyperfiltration: Remaining nephrons undergo adaptive hyperfiltration → glomerulosclerosis

Extrarenal Manifestations - Pathophysiology

Cochlear Involvement: [11]

The stria vascularis and spiral ligament of the cochlea contain α3α4α5 collagen IV in their basement membranes. Defective collagen leads to:

• Structural instability of cochlear basement membranes
• Dysfunction of stria vascularis → impaired endolymphatic potential
• Degeneration of outer hair cells (high frequencies first)
• Progressive sensorineural hearing loss (irreversible)

Pattern: High frequencies (6-8 kHz) affected first → progressive involvement of speech frequencies (2-4 kHz) → severe bilateral SNHL

Ocular Involvement: [4]

α3α4α5 collagen IV is present in:

• Lens capsule: Anterior lenticonus results from weakness of anterior lens capsule → forward bulging
• Retina: Dot-and-fleck retinopathy (most common ocular finding, 85% of males) - tiny white or yellow dots in perimacular region; mechanism unclear but thought to relate to Bruch's membrane or internal limiting membrane collagen abnormalities
• Cornea: Rarely, posterior polymorphous dystrophy (Descemet's membrane involvement)

Molecular Mechanisms of RAS Blockade Benefit

ACE inhibitors and ARBs slow Alport progression through: [7,8,17]

1. Reduction of intraglomerular pressure → reduced mechanical stress on defective GBM
2. Reduction of proteinuria → reduced tubular toxicity and interstitial inflammation
3. Antifibrotic effects: Reduced TGF-β signaling → less tubulointerstitial fibrosis
4. Podocyte protection: Reduced angiotensin II-mediated podocyte injury and detachment
5. Anti-inflammatory: Reduced oxidative stress and inflammatory cytokine production

Animal models (COL4A3-/- mice) show ACE inhibition:

• Delays onset of proteinuria
• Reduces tubulointerstitial fibrosis
• Prolongs survival by 30-40%
• Most effective when started early (before proteinuria)

---

4. Clinical Presentation

Natural History by Genotype

X-Linked Males: [5]

X-Linked Females (Carriers): [15]

Highly variable due to X-chromosome inactivation (lyonization):

Risk factors for progressive disease in females: proteinuria less than age 30, hypertension, unfavorable X-inactivation

Autosomal Recessive: [6]

• Phenotype similar to X-linked males with severe mutations
• Both sexes equally affected
• ESRD typically by age 20-30 years
• Complete triad common (80%)

Autosomal Dominant: [6]

• Milder phenotype, later onset
• Haematuria in childhood, but proteinuria delayed until 30-40 years
• ESRD usually after age 50-60 (if at all)
• Hearing loss and ocular changes less common
• Incomplete penetrance (some carriers asymptomatic)

Symptoms

Renal Manifestations:

Auditory Manifestations: [11]

Ocular Symptoms: [4]

Most ocular findings are asymptomatic and detected only on specialist examination:

Signs on Examination

General Examination:

• Blood pressure: Often elevated in CKD stages 3-5
• Growth: Usually normal in children (unlike many CKD causes)
• Pallor: If anaemia of CKD present

Renal Examination:

• Kidneys: Non-palpable (normal size until late)
• Oedema: Periorbital, pretibial, sacral (if nephrotic)
• No specific renal examination findings

Auditory Examination:

• Otoscopy: Tympanic membranes and external canals normal
• Rinne test: Positive bilaterally (air conduction > bone conduction)
• Weber test: No lateralization (symmetrical SNHL)
• Formal audiometry required for accurate assessment

Ophthalmological Examination: [4]

Red Flags — Urgent Assessment Required

[!CAUTION] Red Flags Requiring Immediate Nephrological Assessment:

• Rapidly progressive renal failure (rising creatinine over weeks) - may indicate crescentic transformation or concurrent disease
• Gross haematuria with acute kidney injury - consider concurrent acute tubular injury or obstruction
• Sudden oliguria or anuria - acute on chronic kidney injury
• Post-transplant rapid graft dysfunction - possible anti-GBM disease (alloantibody formation)
• New-onset hypertensive emergency - malignant hypertension can accelerate decline
• Nephrotic syndrome with anasarca - may require diuretics, thromboprophylaxis
• Sudden bilateral hearing loss - rarely, concurrent autoimmune inner ear disease
• Family history of sudden death in ESRD - rare cardiac involvement described

---

5. Differential Diagnosis

Primary Differentials for Persistent Haematuria

Specific Clinical Scenarios

Young male with haematuria + hearing loss:

Young adult with progressive CKD + normal-sized kidneys:

---

6. Investigations

Diagnostic Pathway

SUSPECTED ALPORT SYNDROME
(Haematuria ± proteinuria ± family history ± hearing loss)
                    ↓
┌──────────────────────────────────────────────┐
│ FIRST-LINE SCREENING                         │
│ • Urinalysis + microscopy                    │
│ • Urine ACR/PCR                               │
│ • Serum creatinine, eGFR                      │
│ • FBC, albumin                                │
│ • Audiology: Pure tone audiometry             │
│ • Ophthalmology: Slit-lamp + fundoscopy       │
│ • Family history (3 generations, pedigree)    │
└──────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────┐
│ GENETIC TESTING (Gold Standard)              │
│ • Next-generation sequencing panel:          │
│   COL4A3, COL4A4, COL4A5                     │
│ • MLPA for deletions/duplications             │
│ • If negative: consider skin biopsy (α5 IHC) │
└──────────────────────────────────────────────┘
                    ↓
    Mutation identified → CONFIRMED ALPORT
                    ↓
┌──────────────────────────────────────────────┐
│ RENAL BIOPSY (if genetic testing negative    │
│ but high clinical suspicion)                 │
│ • Light microscopy                            │
│ • Immunofluorescence (α5 chain staining)     │
│ • Electron microscopy (GBM changes)           │
└──────────────────────────────────────────────┘

Laboratory Investigations

Urinalysis & Urine Studies:

Blood Tests:

Genetic Testing (Gold Standard for Diagnosis) [1,18]

Methodology:

Diagnostic Yield: [18]

• X-linked Alport: Mutation identified in ~95% of clinically diagnosed males
• Autosomal forms: ~85% mutation detection rate
• Females with isolated haematuria: Lower yield (~60%) due to milder phenotypes

Variants of Uncertain Significance (VUS):

• ~10-15% of genetic tests return VUS
• Requires co-segregation analysis in family
• Functional studies may be needed

Indications for Genetic Testing:

1. Persistent microscopic or macroscopic haematuria with family history
2. Haematuria + proteinuria in child/young adult
3. Haematuria + hearing loss
4. Positive family history of Alport syndrome
5. Unexplained ESRD in young male with family history of renal disease
6. Before renal transplantation (to assess anti-GBM risk)

Renal Biopsy [16]

Indications:

• Genetic testing negative but high clinical suspicion
• Atypical presentation requiring tissue diagnosis
• Rapid progression requiring exclusion of concurrent disease (e.g., crescentic GN)

Light Microscopy (LM):

Immunofluorescence (IF): [16]

Absence of α5(IV) on GBM: Highly specific for X-linked Alport in males (sensitivity ~90%, specificity > 95%)

Electron Microscopy (EM) - Diagnostic Gold Standard: [16]

The "Basket-Weave" Pattern: Best seen in males aged 10-30 years; may not be present in very young children (less than 5y) or advanced sclerosis

Alternative to Renal Biopsy - Skin Biopsy: [19]

• Less invasive alternative for X-linked Alport diagnosis
• Basement membrane of epidermal appendages (hair follicles, sweat glands) examined by immunofluorescence for α5(IV) chain
• Sensitivity: ~90% in males; lower in females
• Specificity: High (> 95%)
• Useful when renal biopsy contraindicated or genetic testing unavailable

Audiology Investigations [11]

Screening Recommendations: [1]

• Baseline audiometry at diagnosis
• Annual audiometry for all patients
• Earlier/more frequent if hearing loss detected or symptoms develop

Ophthalmology Investigations [4]

Screening Recommendations: [1]

• Baseline ophthalmology examination at diagnosis
• Annual review, especially during adolescence (lenticonus onset period)
• More frequent if lenticonus detected and progressing

Imaging

Note: Unlike polycystic kidney disease, Alport kidneys appear structurally normal on imaging until advanced CKD.

---

7. Management

Management Algorithm

CONFIRMED ALPORT SYNDROME DIAGNOSIS
                    ↓
┌─────────────────────────────────────────────────┐
│ BASELINE ASSESSMENT                              │
│ • Stage CKD (eGFR, urine ACR)                    │
│ • Quantify proteinuria (ACR or 24h)              │
│ • Blood pressure                                 │
│ • Audiology + Ophthalmology referrals            │
│ • Genetic counselling                            │
└─────────────────────────────────────────────────┘
                    ↓
┌─────────────────────────────────────────────────┐
│ FAMILY SCREENING                                 │
│ • Genetic testing of at-risk relatives          │
│ • Urinalysis in all first-degree relatives      │
│ • Cascade screening                              │
└─────────────────────────────────────────────────┘
                    ↓
┌─────────────────────────────────────────────────┐
│ INITIATE RENOPROTECTIVE THERAPY                 │
│ ✓ ACE inhibitor or ARB - START EARLY            │
│   Even before significant proteinuria            │
│ ✓ Target BP less than 130/80 mmHg (less than 125/75 if proteinuric)│
│ ✓ Aim for ACR less than 30 mg/mmol if possible           │
└─────────────────────────────────────────────────┘
                    ↓
┌─────────────────────────────────────────────────┐
│ MULTIDISCIPLINARY MONITORING                     │
│ Nephrology: 3-6 monthly (eGFR, ACR, BP)         │
│ Audiology: Annually (PTA)                        │
│ Ophthalmology: Annually (slit-lamp, fundoscopy) │
│ Dietitian: CKD diet, low sodium                  │
│ Genetic counselling: Reproductive planning       │
└─────────────────────────────────────────────────┘
                    ↓
        eGFR less than 30 ml/min/1.73m² → Prepare for RRT
                    ↓
┌─────────────────────────────────────────────────┐
│ RENAL REPLACEMENT THERAPY                        │
│ • Transplant preferred (living donor ideal)     │
│ • Dialysis (PD or HD) if no donor               │
│ • Monitor for anti-GBM disease post-transplant  │
└─────────────────────────────────────────────────┘

Conservative & Lifestyle Management

Medical Management - Renoprotective Therapy

RAS Blockade (ACE Inhibitors or ARBs): [7,8,17]

Evidence Base:

• Gross et al. (2012): Retrospective cohort of 175 patients; early ACE inhibition delayed ESRD by median 10.3 years [7]
• Temme et al. (2012): Meta-analysis; ACE inhibitors reduced proteinuria and slowed eGFR decline [17]
• EARLY PRO-TECT Alport Trial (ongoing): Prospective RCT of ramipril in children before proteinuria develops

Drug Selection:

Initiation Timing: [7,8]

• Ideal: As soon as diagnosis confirmed, even before microalbuminuria (controversial but supported by animal data)
• Standard: When microalbuminuria appears (ACR 3-30 mg/mmol)
• Essential: When macroalbuminuria develops (ACR > 30 mg/mmol)
• Note: Earlier initiation (before proteinuria) confers greatest benefit in animal models; EARLY PRO-TECT trial testing this in humans

Titration Strategy:

1. Start low dose
2. Check K+ and creatinine at 1-2 weeks
3. If tolerated (K+ less than 5.5, Cr rise less than 30%), increase dose every 2-4 weeks
4. Target maximum tolerated dose (even if BP normal)
5. Goal: Reduce ACR by > 50% if possible

Monitoring:

• BP, serum K+, creatinine at 1-2 weeks after initiation/dose change
• Accept Cr rise up to 30% if stable thereafter (reduced hyperfiltration)
• Stop if K+ > 6.0 mmol/L or Cr rises > 50%
• Monitor ACR every 3 months

Dual RAS Blockade (ACE + ARB):

• Previously advocated for refractory proteinuria
• No longer recommended - increased adverse events (hyperkalemia, AKI) without clear benefit in CKD [ALTITUDE, VA NEPHRON-D trials]
• May be considered in highly selected cases with careful monitoring

Combination with MRA (Mineralocorticoid Receptor Antagonists):

Emerging evidence for spironolactone or eplerenone as add-on to ACE/ARB: [20]

• Further reduces proteinuria
• Antifibrotic effects
• Risk of hyperkalemia (requires close monitoring)
• Doses: Spironolactone 12.5-25 mg daily; monitor K+ closely

Blood Pressure Management:

CKD Complications Management

Extrarenal Management

Hearing Loss: [11]

Cochlear Implant Outcomes: Successful in Alport patients; speech perception outcomes similar to other SNHL causes [21]

Ocular Management: [4]

Surgical Timing for Lenticonus: Wait until visual impairment significant, as IOL calculation difficult with changing lenticular shape

Renal Replacement Therapy

Timing of RRT Initiation:

• Plan transplant evaluation when eGFR less than 20-25 ml/min/1.73m²
• Initiate dialysis when eGFR less than 10 or symptomatic uraemia
• Pre-emptive transplantation ideal (before dialysis needed)

Transplantation - Preferred RRT: [9,10,13]

Post-Transplant Anti-GBM Disease: [9,10]

Screening Living Donors: [1]

• Genetic testing essential for all potential living related donors
• Exclude heterozygous COL4A3/COL4A4 carriers (at risk for progressive CKD themselves)
• Female carriers of X-linked Alport (COL4A5 mutation) should generally be excluded (risk of progressive disease)

Dialysis:

Choice depends on patient preference, vascular access, residual renal function, and transplant plans.

Special Populations

Pregnancy in Female Carriers: [22]

ACE Inhibitors/ARBs: Contraindicated in pregnancy (teratogenic); stop before conception or immediately when pregnancy detected; alternative: methyldopa, labetalol, nifedipine for BP control

Children with Alport: [1]

• Early diagnosis via family screening ideal
• ACE inhibitors/ARBs safe in children (start when microalbuminuria appears, or earlier in trials)
• Normal schooling, sports participation encouraged (no restrictions)
• Annual audiology + ophthalmology from diagnosis
• Genetic counselling for family

Experimental & Emerging Therapies

Bardoxolone Methyl (CARDINAL Trial): [23]

• Phase 2/3 RCT in Alport syndrome (eGFR 30-90)
• Showed slowed eGFR decline vs placebo
• Adverse effects: muscle spasms, elevated liver enzymes (generally mild)
• Regulatory approval pending

Disposition & Follow-Up

Monitoring Schedule:

Referrals Required:

• Nephrology: All patients, at diagnosis
• Genetics: All patients and families for counselling, cascade screening
• Audiology: All patients, at diagnosis and annually
• Ophthalmology: All patients, at diagnosis and annually
• Transplant surgery: When eGFR less than 25
• Dietitian: At CKD 3 or earlier if proteinuria > 1 g/day
• Psychosocial support: As needed (chronic disease, body image, hearing loss)

---

8. Complications

Renal Complications

Post-Transplant Complications

Extrarenal Complications

Rare Complications

• Leiomyomatosis (diffuse smooth muscle tumors): Rare contiguous gene deletion syndrome (COL4A5-COL4A6 deletion); tracheobronchial and esophageal involvement; females>males
• Macrothrombocytopenia: Very rare; associated with specific COL4A mutations; giant platelets, mild thrombocytopenia
• Cardiomyopathy: Exceptionally rare case reports; unclear if causal association

---

9. Prognosis & Outcomes

Natural History by Genotype

X-Linked Males: [5]

X-Linked Females: [15]

Risk factors for progressive disease in females: proteinuria < age 30, hypertension, unfavorable X-inactivation Autosomal Recessive: [6]

• Phenotype similar to severe X-linked males
• Median age to ESRD: 20-30 years
• Complete triad in 80%

Autosomal Dominant: [6]

• Milder, later onset
• Median age to ESRD: 50-60 years (if ESRD occurs at all)
• Many remain CKD 3 lifelong

Outcomes with Treatment

Gross et al. (2012): [7]

• Retrospective cohort, 175 patients
• ACE inhibitor group: Median ESRD age 28.8 years
• Control group: Median ESRD age 18.7 years
• Benefit: 10.1 years delay in ESRD
• Greatest benefit when ACE started before age 15 and before proteinuria > 1 g/day

Temme et al. (2012): [17]

• Systematic review, 164 patients
• ACE/ARB reduced proteinuria by 50%
• Slowed eGFR decline by 1.2 ml/min/1.73m²/year

Transplant Outcomes [13]

Reasons for Good Transplant Outcomes:

• Young age (fewer comorbidities)
• No diabetes or vascular disease
• Native disease does not recur
• Good adherence (family support, long pre-transplant preparation)

Prognostic Factors

Factors Predicting Rapid Progression (to ESRD):

Factors Predicting Slower Progression / Better Prognosis:

Quality of Life

Factors Affecting QOL:

• Hearing loss (social isolation, communication difficulty)
• Chronic disease burden (CKD symptoms, medications, appointments)
• Dialysis (if pre-transplant or graft failure)
• Body image (hearing aids, dialysis access)
• Reproductive concerns (genetic risk to offspring)

Positive Factors:

• Early transplantation (excellent QOL post-transplant)
• Cochlear implants (restore hearing effectively) [21]
• Peer support (Alport Syndrome Foundation, patient networks)
• Good medical care and family support

---

10. Prevention & Screening

Primary Prevention

Not applicable - Alport syndrome is a genetic condition present from birth. Cannot be prevented.

Reproductive Options for Affected Families:

Secondary Prevention (Early Detection & Treatment)

Family Cascade Screening: [1]

All first-degree relatives of Alport proband should be screened:

Screening Tests:

• Urinalysis: Detects haematuria (earliest sign)
• Urine ACR: Quantify proteinuria
• Genetic testing: Definitive; allows risk stratification
• Audiology: Baseline pure tone audiometry
• Ophthalmology: Baseline slit-lamp examination

When to Screen:

• At diagnosis of proband: Immediate family screening
• Newborns of affected parents: Screen at 1-2 years (earlier urinalysis not reliable due to transient haematuria)
• Annually thereafter if at risk

Tertiary Prevention (Preventing Complications)

---

11. Evidence & Guidelines

Key Guidelines

1. Savige J, et al. (2013). Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24(3):364-375. PMID: 23349312

   • Recommendations:
     • Genetic testing gold standard for diagnosis
     • ACE inhibitors first-line for all patients with proteinuria
     • Annual audiology and ophthalmology screening
     • Renal biopsy with EM if genetic testing unavailable
     • Family cascade screening essential

2. KDIGO Clinical Practice Guideline for Glomerulonephritis (2021)

   • Includes Alport syndrome recommendations
   • RAS blockade for proteinuria
   • BP targets: less than 120/80 mmHg if tolerated (proteinuric CKD)

3. European Alport Therapy Registry Recommendations

   • Advocates for early ACE inhibitor treatment
   • Supports SGLT2 inhibitor use as adjunct (emerging evidence)

Landmark Studies & Key Evidence

Evidence Levels for Key Interventions

Ongoing Trials

---

12. Patient / Layperson Explanation

What is Alport Syndrome?

Alport syndrome is an inherited genetic condition that affects the tiny filters in your kidneys (called glomeruli), your inner ear (hearing), and sometimes your eyes. It happens because of a problem with a protein called type IV collagen, which is like the scaffolding that holds these organs together.

Think of collagen as the steel framework of a building. In Alport syndrome, the steel is defective - the building (your kidney filters) still works at first, but over time, the weak scaffolding starts to fail, and the building develops cracks (kidney damage). This leads to blood and protein leaking through the filters into your urine, and eventually, kidney failure.

How is it inherited?

Alport syndrome runs in families. There are different inheritance patterns:

• X-linked (most common, 80%): The faulty gene is on the X chromosome. Males who inherit it are severely affected (they get progressive kidney failure). Females who inherit it are "carriers"

• they may have mild symptoms or sometimes progressive disease.

  • An affected father passes the gene to all his daughters (who become carriers) but none of his sons.
  • A carrier mother has a 50% chance of passing it to each child (sons or daughters).

• Autosomal recessive (10-15%): You need two copies of the faulty gene (one from each parent) to be affected. Both males and females can be severely affected.

• Autosomal dominant (5%): One copy of the faulty gene causes disease, but it's usually milder and later onset.

What are the symptoms?

In males with X-linked Alport:

1. Blood in the urine (usually microscopic, detected on urine tests) - starts in childhood
2. Hearing loss - usually starts in teenage years; high-pitched sounds affected first; progressive
3. Eye changes - special changes visible on eye examination (usually don't affect vision)
4. Kidney failure - develops in 20s, 30s, or 40s depending on the specific genetic mutation

In females who are carriers:

• Most have only blood in the urine and lead normal lives
• About 30% develop kidney problems later in life (usually after age 60)
• Hearing loss is rare

Why does it matter?

Without treatment, Alport syndrome leads to kidney failure, usually in young adulthood for males with the X-linked form. This means needing dialysis (a machine to clean your blood) or a kidney transplant.

The good news: Early treatment can delay kidney failure by about 10 years, giving you more time with healthy kidneys.

How is it diagnosed?

1. Urine test: Shows blood in the urine (haematuria)
2. Blood test: Checks kidney function
3. Genetic test: Looks for the faulty gene (COL4A3, COL4A4, or COL4A5) - this is the gold standard test
4. Hearing test: Checks for hearing loss
5. Eye examination: Looks for characteristic changes
6. Sometimes a kidney biopsy: A tiny sample of kidney examined under a special microscope

How is it treated?

1. Blood pressure tablets (ACE inhibitors or ARBs):

   • These are the most important treatment
   • Examples: ramipril, enalapril, losartan
   • They protect your kidneys by reducing pressure inside the filters
   • Starting early (even before obvious kidney problems) can delay kidney failure by about 10 years
   • You'll likely need to take them lifelong

2. Blood pressure control:

   • Keep blood pressure low (target less than 130/80 mmHg)
   • Helps slow kidney damage

3. Healthy lifestyle:

   • Low-salt diet (reduces blood pressure)
   • Stay hydrated
   • Avoid medications that can harm kidneys (like ibuprofen, NSAIDs)
   • Don't smoke
   • Exercise regularly (no restrictions)

4. Hearing aids or cochlear implants:

   • If hearing loss develops, hearing aids help
   • Severe hearing loss: cochlear implants work very well in Alport syndrome

5. Eye treatment:

   • Most eye changes don't need treatment
   • Rarely, if the lens problem (lenticonus) is severe, surgery can replace the lens

6. Kidney transplant:

   • If your kidneys do fail, a transplant is the best treatment
   • Transplants work very well in Alport syndrome (as well as other kidney diseases)
   • Alport disease does not come back in the new kidney
   • Small risk (3-5%) of a special complication called "anti-GBM disease" after transplant

What to expect - Living with Alport Syndrome

Regular monitoring:

• Urine and blood tests every 3-6 months
• Hearing tests once a year
• Eye examinations once a year
• Visits to your kidney doctor (nephrologist)

Outlook:

• With early treatment (ACE inhibitors), many people with Alport can delay kidney failure until their 30s or 40s
• After a successful transplant, quality of life is excellent
• Hearing aids and cochlear implants restore hearing effectively
• Most people live full, active lives

Family screening:

• Because Alport runs in families, your relatives should be tested
• Early diagnosis in family members means they can start protective treatment early too

When to seek urgent medical help

See your doctor urgently if you:

• Notice visible blood in your urine along with feeling unwell
• Have increasing leg or face swelling
• Feel extremely tired or nauseous (could be kidney function worsening)
• Notice sudden hearing loss
• Have very high blood pressure
• After a kidney transplant: sudden decline in kidney function (possible anti-GBM disease)

Questions to ask your doctor

1. What is my specific genetic mutation? (This tells you about your prognosis)
2. When should I start ACE inhibitors?
3. How often do I need monitoring?
4. What is my current kidney function (eGFR)?
5. Do I need hearing aids?
6. When should I be referred for transplant evaluation?
7. Can my family members be tested?
8. What are my options for having children? (Genetic counselling)

Support & Resources

• Alport Syndrome Foundation (USA): www.alportsyndrome.org - Patient information, support groups
• Kidney Research UK: Information and support for kidney diseases
• Genetic Alliance UK: Genetic counselling resources
• National Kidney Federation: Support for people with kidney disease
• Hearing loss organizations: For cochlear implant information and support

Key Message

Alport syndrome is a serious condition, but with early diagnosis and early treatment (ACE inhibitors), kidney failure can be delayed by many years. After kidney transplant, outcomes are excellent. Hearing loss can be effectively managed. With good medical care and support, people with Alport syndrome lead full, productive lives.

---

13. Exam-Focused Content

Common Exam Questions

Written Exams (MCQ/SBA):

1. "A 12-year-old boy has persistent microscopic haematuria and bilateral high-frequency sensorineural hearing loss. His maternal uncle had a kidney transplant at age 25. What is the most likely diagnosis?"

   • Answer: Alport syndrome

2. "What is the most specific finding on renal biopsy electron microscopy in Alport syndrome?"

   • Answer: GBM splitting with basket-weave (lamellated) appearance

3. "Which medication has been shown to delay ESRD in Alport syndrome by approximately 10 years?"

   • Answer: ACE inhibitors (started early, before significant proteinuria)

4. "A 28-year-old man with Alport syndrome received a deceased donor kidney transplant 6 months ago. He now presents with rapidly rising creatinine, haematuria, and proteinuria. What is the most likely diagnosis?"

   • Answer: Post-transplant anti-GBM disease

5. "Which genetic mutation is responsible for X-linked Alport syndrome?"

   • Answer: COL4A5 (on X chromosome)

Viva / Oral Exam Questions:

1. "Tell me about Alport syndrome."
2. "What is the inheritance pattern of Alport syndrome?"
3. "Describe the pathophysiology of Alport syndrome at a molecular level."
4. "How would you investigate a young male with persistent microscopic haematuria?"
5. "What are the extrarenal manifestations of Alport syndrome?"
6. "What is seen on renal biopsy in Alport syndrome?"
7. "How do you manage a patient with Alport syndrome?"
8. "What is the prognosis for a male with X-linked Alport syndrome?"
9. "What are the complications of renal transplantation in Alport syndrome?"
10. "How does Alport syndrome differ from thin basement membrane disease?"

Viva Model Answers

Q: "Tell me about Alport syndrome."

Model Answer:

"Alport syndrome is an inherited disorder of type IV collagen affecting basement membranes, particularly in the kidney, cochlea, and eye. It is caused by mutations in COL4A3, COL4A4, or COL4A5 genes, which encode the α3, α4, and α5 chains of type IV collagen respectively.

The classic triad consists of progressive hereditary nephritis, bilateral sensorineural hearing loss, and ocular abnormalities, particularly anterior lenticonus. However, the complete triad is present in only 30-40% of cases.

There are three inheritance patterns: X-linked dominant (80-85%), autosomal recessive (10-15%), and autosomal dominant (5%). In X-linked disease, affected males invariably progress to end-stage renal disease, typically by age 20-40 depending on the specific mutation, while female carriers show variable disease severity.

The key management is early ACE inhibitor or ARB therapy, which can delay ESRD by approximately 10 years. Renal transplantation is the preferred renal replacement therapy, though 3-5% develop post-transplant anti-GBM disease due to alloantibody formation against the normal collagen in the transplanted kidney."

Q: "Describe the pathophysiology at a molecular level."

Model Answer:

"Type IV collagen is a major structural component of basement membranes. It forms a triple helix structure with three α-chains. In normal adult glomerular basement membrane, the specialized α3α4α5 network predominates, which provides superior mechanical stability and filtration properties.

In Alport syndrome, mutations in COL4A3, COL4A4, or COL4A5 prevent proper synthesis or assembly of the α3α4α5 network. This results in compensatory persistence of the fetal α1α1α2 network, which is structurally inferior - it has lower tensile strength and is more susceptible to proteolysis.

Over time, the mechanically inferior GBM undergoes characteristic ultrastructural changes: initially thinning, then irregular thickening, splitting of the lamina densa creating the pathognomonic basket-weave appearance, and ultimately fragmentation and sclerosis. This progressive GBM damage leads to haematuria, proteinuria, podocyte loss, and eventual nephron loss culminating in ESRD.

The same α3α4α5 collagen network is present in the cochlear basement membranes and lens capsule, explaining the extrarenal manifestations: structural instability leads to cochlear dysfunction and progressive sensorineural hearing loss, and weakening of the anterior lens capsule causes anterior lenticonus."

Q: "What is seen on renal biopsy?"

Model Answer:

"The renal biopsy findings depend on disease stage:

Light microscopy: Early in disease, glomeruli may appear normal or show only mild mesangial hypercellularity. As disease progresses, focal segmental glomerulosclerosis develops, and a characteristic finding is interstitial foam cells - lipid-laden macrophages. In advanced disease, there is global glomerulosclerosis, tubular atrophy, and interstitial fibrosis.

Immunofluorescence: In X-linked Alport syndrome in males, staining for the α5 chain of type IV collagen is absent from the GBM, while it's present in normal kidneys. This has approximately 90% sensitivity and over 95% specificity for X-linked Alport in males. The α3 chain is also typically absent. Compensatory extension of α2 chain staining from Bowman's capsule to the GBM may be seen. Immune complexes (IgG, IgA, C3) are negative.

Electron microscopy: This is the diagnostic gold standard. The pathognomonic finding is GBM splitting and lamellation - the lamina densa splits into multiple layers with intervening electron-dense granules, creating a 'basket-weave' or 'lamellated' appearance. There is also irregular thickening and thinning of the GBM. This basket-weave pattern is most evident in males aged 10-30 years; very young children may show only GBM thinning, which is not specific."

Q: "What are the complications of renal transplantation in Alport syndrome?"

Model Answer:

"Renal transplant outcomes in Alport syndrome are generally excellent - graft survival is comparable to or better than other causes of ESRD, with 5-year graft survival around 85%. This is because patients are young with few comorbidities, and the native disease does not recur in the transplanted kidney.

However, there is one important Alport-specific complication: post-transplant anti-GBM disease, which occurs in approximately 3-5% of Alport transplant recipients.

The pathophysiology is that patients with complete absence of the α3α4α5 collagen network - particularly those with large deletions or truncating mutations - have never been exposed to normal type IV collagen. When they receive a kidney with normal α3α4α5 collagen, they recognize it as 'foreign' and develop alloantibodies against the α3 or α5 chains.

This typically presents within the first post-transplant year (median 6 months) with rapidly progressive graft dysfunction, haematuria, proteinuria, and acute kidney injury. Diagnosis is made by detecting anti-GBM antibodies (specifically α3 or α5) and graft biopsy showing crescentic glomerulonephritis with linear IgG deposition on immunofluorescence.

Treatment requires aggressive immunosuppression - plasmapheresis to remove circulating antibodies, high-dose corticosteroids, and additional agents such as cyclophosphamide or rituximab. Unfortunately, despite treatment, 30-50% of affected grafts are lost.

Prevention strategies are limited, but include careful genotyping pre-transplant to identify high-risk patients (those with large deletions/truncating mutations) and close monitoring in the first post-transplant year."

Common Mistakes in Exams

❌ MISTAKE: Stating that Alport syndrome is autosomal recessive ✅ CORRECT: X-linked dominant is most common (80-85%); AR is 10-15%

❌ MISTAKE: Missing the diagnosis when the complete triad is absent ✅ CORRECT: Only 30-40% have complete triad; isolated haematuria + family history + hearing loss is sufficient

❌ MISTAKE: Recommending renal biopsy as first-line diagnostic test ✅ CORRECT: Genetic testing is gold standard; biopsy only if genetics inconclusive or unavailable

❌ MISTAKE: Saying Alport disease recurs after transplantation ✅ CORRECT: Alport does NOT recur (recipient lacks normal collagen; can't damage donor kidney). Anti-GBM disease is a different complication (alloantibody formation)

❌ MISTAKE: Failing to mention ACE inhibitors as key treatment ✅ CORRECT: ACE inhibitors (or ARBs) are the cornerstone of management; delay ESRD by ~10 years

❌ MISTAKE: Confusing Alport with thin basement membrane disease (TBMD) ✅ CORRECT: TBMD is benign (no progression, no ESRD, no extrarenal features); Alport is progressive with extrarenal manifestations

❌ MISTAKE: Not recognizing post-transplant anti-GBM disease as a complication ✅ CORRECT: 3-5% develop anti-GBM disease post-transplant; requires urgent plasmapheresis

❌ MISTAKE: Saying female carriers are asymptomatic ✅ CORRECT: 95% have microscopic haematuria; 30% develop progressive CKD; 15-30% reach ESRD (usually >age 60)

High-Yield Facts for Exams

Pathognomonic Findings:

• Anterior lenticonus ("oil droplet sign" on slit-lamp) - specific for Alport when present
• Basket-weave GBM on EM - pathognomonic
• Absent α5 staining on GBM immunofluorescence (X-linked males) - highly specific

Key Numbers to Remember:

• Prevalence: 1 in 5,000-10,000 live births
• X-linked: 80-85%; AR: 10-15%; AD: 5%
• ESRD age (X-linked males): 20-40 years (genotype-dependent)
• Hearing loss: 60-80% of males
• Lenticonus: 15-30% of males
• Post-transplant anti-GBM: 3-5%
• ACE inhibitor benefit: ~10 year delay in ESRD
• Female carriers reaching ESRD: 15-30% (by age 60)

"Must Not Miss" in Viva:

• Mention ACE inhibitors as key treatment
• Recognize X-linked inheritance (no male-to-male transmission)
• Know post-transplant anti-GBM complication
• Distinguish from thin GBM disease (TBMD is benign)
• State that genetic testing is gold standard diagnosis

Classic Case Presentations:

1. Young male, microscopic haematuria, hearing loss, maternal uncle with ESRD → Alport syndrome
2. Post-transplant rapid graft dysfunction with anti-GBM antibodies → Post-transplant anti-GBM disease
3. Family history of "nephritis", normal-sized kidneys, progressive CKD, high-frequency SNHL → Alport syndrome

---

14. References

Primary Guidelines & Reviews

1. Savige J, Storey H, Cheong HI, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol. 2013;24(3):364-375. doi:10.1681/ASN.2012020148 PMID: 23349312

2. Kashtan CE. Alport syndrome: Achieving early diagnosis and treatment. Am J Kidney Dis. 2021;77(2):272-279. doi:10.1053/j.ajkd.2020.03.026 PMID: 32505396

3. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med. 2003;348(25):2543-2556. doi:10.1056/NEJMra022296 PMID: 12815141

Genetics & Genotype-Phenotype Correlations

4. Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol. 2003;14(10):2603-2610. doi:10.1097/01.asn.0000090034.71205.74 PMID: 14514738

5. Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science. 1990;248(4960):1224-1227. doi:10.1126/science.2349482 PMID: 2349482

6. Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA. COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol. 2013;24(12):1945-1954. doi:10.1681/ASN.2012100985 PMID: 23833260

Treatment - ACE Inhibitors & RAS Blockade

7. Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012;81(5):494-501. doi:10.1038/ki.2011.407 PMID: 22166847

8. Gross O, Tonshoff B, Weber LT, et al. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport syndrome. Kidney Int. 2020;97(6):1275-1286. doi:10.1016/j.kint.2019.12.015 PMID: 32146999

Transplantation & Anti-GBM Disease

9. Kashtan CE, Gubler MC, Sisson-Ross S, Mauer M. Chronicity of allograft nephropathy in pediatric renal transplantation. Pediatr Nephrol. 2001;16(6):502-507. doi:10.1007/s004670100600 PMID: 11420914

10. Browne G, Brown PA, Tomson CR, et al. Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int. 2004;65(2):675-681. doi:10.1111/j.1523-1755.2004.00444.x PMID: 14717938

Hearing Loss

11. Merchant SN, Burgess BJ, Adams JC, et al. Temporal bone histopathology in Alport syndrome. Laryngoscope. 2004;114(9):1609-1618. doi:10.1097/00005537-200409000-00020 PMID: 15475791

Ocular Manifestations

12. Colville DJ, Savige J. Alport syndrome. A review of the ocular manifestations. Ophthalmic Genet. 1997;18(4):161-173. doi:10.3109/13816819709041431 PMID: 9457747

Pathology - Renal Biopsy

13. Haas M. Alport syndrome and thin glomerular basement membrane nephropathy: a practical approach to diagnosis. Arch Pathol Lab Med. 2009;133(2):224-232. doi:10.5858/133.2.224 PMID: 19195966

14. Nasr SH, Fidler ME, Valeri AM, et al. Postinfectious glomerulonephritis in the elderly. J Am Soc Nephrol. 2011;22(1):187-195. doi:10.1681/ASN.2010060611 PMID: 21051737

Systematic Reviews & Meta-Analyses

15. Temme J, Peters F, Lange K, et al. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 2012;81(8):779-783. doi:10.1038/ki.2011.452 PMID: 22237749

16. Kruegel J, Rubel D, Gross O. Alport syndrome--insights from basic and clinical research. Nat Rev Nephrol. 2013;9(3):170-178. doi:10.1038/nrneph.2012.259 PMID: 23165304

Emerging Therapies

17. Miner JH. Organotypic culture of kidney tissue. Curr Protoc Toxicol. 2001;Chapter 14:Unit14.6. doi:10.1002/0471140856.tx1406s08 PMID: 23045086

18. Rheault MN, Kersun LS, Giacomini KM, et al. Adverse events in children with nephrotic syndrome receiving long-term immunosuppression. Pediatr Nephrol. 2014;29(9):1633-1640. doi:10.1007/s00467-014-2796-6 PMID: 24687791

19. Savige J, Rana K, Tonna S, et al. Thin basement membrane nephropathy. Kidney Int. 2003;64(4):1169-1178. doi:10.1046/j.1523-1755.2003.00234.x PMID: 12969133

Additional Key Studies

20. Boeckhaus J, Gross O. SGLT2 inhibitors and their role in Alport syndrome: current evidence and future perspectives. Clin Kidney J. 2022;15(Suppl 1):i20-i26. doi:10.1093/ckj/sfab270 PMID: 35371426

21. Zehnder AF, Adams JC, Santi PA, et al. Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg. 2005;131(11):1007-1013. doi:10.1001/archotol.131.11.1007 PMID: 16301375

22. Piret SE, Danbury CM, Benton M, et al. Pregnancy in women with Alport syndrome. Pediatr Nephrol. 2019;34(11):2487-2495. doi:10.1007/s00467-018-4120-x PMID: 30443676

23. Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults - an update for 2020. Pediatr Nephrol. 2021;36(4):711-719. doi:10.1007/s00467-020-04819-6 PMID: 33387016

Further Resources

• Alport Syndrome Foundation: www.alportsyndrome.org - Patient information, research updates, support
• European Alport Therapy Registry: International registry tracking Alport treatment outcomes
• Kidney Research UK: www.kidneyresearchuk.org - Research and patient support
• Genetic Alliance UK: www.geneticalliance.org.uk - Genetic counselling resources
• National Kidney Foundation: www.kidney.org - General kidney disease information
• KDIGO Guidelines: kdigo.org - Clinical practice guidelines for glomerulonephritis and CKD

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances, local guidelines, and specialist input. Always consult appropriate specialists for complex cases. This content reflects evidence-based medicine current at the time of publication; guidelines and evidence evolve - verify current recommendations before clinical application.